Mebufotenin is under clinical development by GH Research and currently in Phase I for Unspecified Psychiatric Disorders. According to GlobalData, Phase I drugs for Unspecified Psychiatric Disorders have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mebufotenin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mebufotenin overview
Mebufotenin (GH-001) is under development for the treatment of treatment-resistant depression, major depressive disorder, bipolar II disorder, post partum depression and other psychiatric diseases. The drug candidate is a 5-methoxy-dimethyltryptamine (5-MEO-DMT). The drug candidate is a drug-device combination. It is administered through the inhalational route. It acts by targeting serotonin 5 HT1A and 5HT2A.
GH Research overview
GH Research biopharmaceutical company developing novel therapies for psychiatric and neurological disorders. The company has desigend its proprietary inhalable 5-MeO-DMT for depression. GH Research is headquartered in Dublin, Ireland.
For a complete picture of Mebufotenin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
